Additional Nitrogen Containing Patents (Class 536/7.4)
  • Patent number: 9493447
    Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 15, 2016
    Assignee: Omeros Corporation
    Inventors: Neil S. Cutshall, Kenneth M. Ferguson, Charles Prince Zuta
  • Patent number: 9200026
    Abstract: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 1, 2015
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Chang-Hsing Liang, Jonathan Duffield, Alex Romero, Yu-Hung Chiu, Steve Sucheck, Kenneth Marby, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang, David Rabuka, Sulan Yao
  • Patent number: 9174973
    Abstract: The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: November 3, 2015
    Assignees: SUNSHINE LAKE PHARMA CO., LTD., RUYUAN HEC PHARM CO., LTD.
    Inventors: Xin Lei, Jinan Peng, Tianming Wang, Zhiqing Lv, Wan Li
  • Patent number: 9139609
    Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 22, 2015
    Assignees: TAISHO PHARMACEUTICAL CO., LTD., MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
  • Patent number: 9006189
    Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 14, 2015
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
  • Patent number: 8993739
    Abstract: A process for the preparation of compound of Formula (I) is provided.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 31, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Kiran Kumar Gangakhedkar, Furqan Mohammed Diwan, Aniruddha Varangaonkar, Keshav Deo
  • Patent number: 8951977
    Abstract: This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterized by the absence of peaks in the infra-red spectrum of amorphous (Form-I11) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterized by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: February 10, 2015
    Assignee: North-West University
    Inventors: Wilna Liebenberg, Marique Aucamp
  • Patent number: 8940880
    Abstract: The present invention concerns a process for the preparation of the compound of formula The compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin, useful to treat bacterial and protozoa infections.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: January 27, 2015
    Assignee: Novartis AG
    Inventors: Rafael Garcia, Oriol Martorell, Albert Codony
  • Patent number: 8901089
    Abstract: The invention relates to an amorphous non-crystalline glass form (Form-II) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm?1. The invention further relates to a preparation method of increasing the solubility of roxithromycin including the steps of selecting anhydrous roxithromycin or monohydrated roxithromycin; elevating the temperature of the roxithromycin to above the melting point thereof; and reducing the temperature of the melt sufficiently to allow it to set into an amorphous non-crystalline glass form (Form-II) of roxithromycin having relatively increased solubility without decreasing the stability of thereof.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: December 2, 2014
    Assignee: North-West University
    Inventors: Wilna Liebenberg, Marique Aucamp, Melgardt M De Villiers
  • Patent number: 8871728
    Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, E is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: October 28, 2014
    Assignee: Georgia Tech Research Corporation
    Inventors: Adegboyega Oyelere, Subhasish Tapadar
  • Patent number: 8865662
    Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: October 21, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 8759500
    Abstract: New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 24, 2014
    Assignee: Cempra Pharmaceuticals, Inc.
    Inventor: David E. Pereira
  • Publication number: 20140094422
    Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R1, R2, etc. are defined as in Claim 1.
    Type: Application
    Filed: June 14, 2013
    Publication date: April 3, 2014
    Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo
  • Publication number: 20140088031
    Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
    Type: Application
    Filed: August 21, 2013
    Publication date: March 27, 2014
    Applicant: RIB-X PHARMACEUTICALS, INC.
    Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
  • Publication number: 20140046043
    Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
    Type: Application
    Filed: February 20, 2012
    Publication date: February 13, 2014
    Applicants: MEIJI SEIKA PHARMA CO., LTD., TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
  • Publication number: 20140031307
    Abstract: The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.
    Type: Application
    Filed: October 10, 2011
    Publication date: January 30, 2014
    Applicant: SYNOVO GMBH
    Inventors: Michael W. Burnet, Jan-Hinrich Guse, Christiane Bauerlein, Mary Eggers
  • Publication number: 20140031302
    Abstract: The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharmaceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90).
    Type: Application
    Filed: October 24, 2011
    Publication date: January 30, 2014
    Applicant: UNIVERSITE DE STRASBOURG
    Inventors: Nicolas Winssinger, Sofia Barluenga
  • Publication number: 20140005133
    Abstract: The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R1 is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R1 is hydrogen, R3 is fluorine.
    Type: Application
    Filed: February 3, 2011
    Publication date: January 2, 2014
    Inventors: Bharat Trivedi, Prasad Deshpande, Ravikumar Tadiparthi, Sunil Gupta, Santosh Diwakar, Shivaji Pawar, Vijay Patil, Deepak Dekhane, Mahesh Patel, Satish Bhavsar, Amit Mishra, Manish Solanki, Mohammad Jafri, Sachin Bhagwat
  • Patent number: 8552162
    Abstract: The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: October 8, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoyou Xu, Datong Tang, In Jong Kim, Ly Tam Phan, Yat Sun Or, Zhe Wang
  • Publication number: 20130197204
    Abstract: The present invention concerns a process for the preparation of the compound of formula The compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin, useful to treat bacterial and protozoa infections.
    Type: Application
    Filed: September 19, 2011
    Publication date: August 1, 2013
    Inventors: Rafael Garcia, Oriol Martorell, Albert Codony
  • Patent number: 8470985
    Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R1, R2, ect. Are defined in claim 1.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: June 25, 2013
    Assignee: Rib-X Pharmaceuticals, Inc.
    Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo
  • Patent number: 8461120
    Abstract: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: June 11, 2013
    Assignee: Synovo GmbH
    Inventors: Hans-Jurgen Gutke, Michael Burnet, Jan-Hinrich Guse
  • Patent number: 8445451
    Abstract: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or, cancer in animals and humans.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: May 21, 2013
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
  • Publication number: 20130102550
    Abstract: This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxy-imino)-3, 5, 7, 9, 11, 13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-III) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water.
    Type: Application
    Filed: April 14, 2011
    Publication date: April 25, 2013
    Applicant: North-West University
    Inventors: Wilna Liebenberg, Marique Aucamp
  • Patent number: 8410065
    Abstract: The invention relates to antibiotic macrolides of formula (I), which have improved anti-inflammatory activity mediated through inhibition of phosphodiesterase 4 (PDE4) useful for the treatment and/or prevention of inflammatory, allergic and proliferative diseases.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: April 2, 2013
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
  • Publication number: 20130066056
    Abstract: The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A.
    Type: Application
    Filed: May 20, 2011
    Publication date: March 14, 2013
    Applicant: CEMPRA PHARMACEUTICALS, INC.
    Inventor: David E. Pereira
  • Publication number: 20130059805
    Abstract: The invention relates to an amorphous non-crystalline glass form (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranoside or azithromycin having an infra-red pattern displaying characteristic relatively broad peaks at approximately 3500 and 1727 cm?1 and characteristic peaks at approximately 2970 and 2938 cm?1. The invention further relates to a preparation method of increasing the solubility of azithromycin including the steps of selecting anhydrous, monohydrated or dihydrated azithromycin; elevating the temperature of the azithromycin to above the melting point thereof; and reducing the temperature of the melt sufficiently to allow it to set into an amorphous non-crystalline glass form (Form-II) of azithromycin having relatively increased solubility without decreasing the structural stability thereof.
    Type: Application
    Filed: December 15, 2010
    Publication date: March 7, 2013
    Applicant: North-West University
    Inventors: Roelf Willem Odendaal, Wilna Liebenberg, Marique Aucamp
  • Patent number: 8383785
    Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit superior antibacterial properties, particularly against Haemophilus influenzae. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: February 26, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Rajesh Iyengar, Yanchun Wang, Ly Tam Phan, Yat Sun Or
  • Patent number: 8354383
    Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: January 15, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Tongzhu Liu, Jiang Long, Guoqiang Wang, Yao-Ling Qiu, Heejin Kim, Yanchun Wang, Ly Tam Phan, Yat Sun Or
  • Patent number: 8349806
    Abstract: The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: January 8, 2013
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Kurt E. Brubaker, Romulus K. Brazzell, Reza M. Haque, John C. Ice, Jr., José L. Boyer, Joseph B. Boyd, Robert J. Dempsey
  • Patent number: 8343936
    Abstract: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: January 1, 2013
    Assignee: Optimer Pharmaceuticals, Inc.
    Inventors: Jonathan Duffield, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang
  • Publication number: 20120329741
    Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, E is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.
    Type: Application
    Filed: May 25, 2012
    Publication date: December 27, 2012
    Inventors: Adegboyega Oyelere, Subhasish Tapadar
  • Patent number: 8314218
    Abstract: The present invention relates to methods for synthesizing macrolide compounds which are known to have antibacterial activity, and are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to methods for synthesizing the macrolide antibiotic, gamithromycin utilizing a novel configuration of catalysts, chemical structures, and/or methods. An embodiment of the present invention may include allowing multiple chemical reactions to proceed without the isolation of chemical intermediates. Thus, multiple reactions may occur in one reaction vessel allowing for a considerable decrease in the cycle-time. The present invention also provides a novel method for inhibiting degradation while isolating a structure of a pharmaceutical composition.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: November 20, 2012
    Assignee: Merial Limited
    Inventors: Zita Mendes, António Carlos Silva Henriques, William Heggie
  • Publication number: 20120277174
    Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
    Type: Application
    Filed: August 13, 2010
    Publication date: November 1, 2012
    Applicant: BASILEA PHARMACEUTICA AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
  • Patent number: 8299035
    Abstract: A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci).
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: October 30, 2012
    Assignees: Taisho Pharmaceutucal Co., Ltd., Meiji Seika Pharma Co., Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Satoshi Yoshida, Kou Kumura, Keiichi Ajito
  • Patent number: 8293715
    Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 23, 2012
    Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara
  • Patent number: 8278281
    Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: October 2, 2012
    Assignee: Rib-X Pharmaceuticals, Inc.
    Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
  • Patent number: 8273720
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: September 25, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Tongzhu Liu, Heejin Kim, Yanchun Wang, Yao-Ling Qiu, Ly Tam Phan, Yat Sun Or
  • Patent number: 8227428
    Abstract: The compound 3?-N-demethyl-4?-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment of neutrophil dominated inflammatory diseases, and methods for its preparation.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Caroline Jane Day, Julien Bruno Douillet, Darko Filic, Leanda Jane Kindon, Goran Kragol, Zorica Marusic-Istuk
  • Patent number: 8222380
    Abstract: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: July 17, 2012
    Assignee: Sandoz AG
    Inventors: Johannes Ludescher, Ulrich Griesser, Christoph Langes
  • Patent number: 8202843
    Abstract: The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R1, R2, R3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 19, 2012
    Assignee: Rib-X Pharmaceuticals, Inc.
    Inventors: Jay J. Farmer, Ashoke Bhattacharjee, Yi Chen, Joel A. Goldberg, Joseph A. Ippolito, Zoltan F. Kanyo, Rongliang Lou, Adegboyega K. Oyelere, Edward C. Sherer, Joyce A. Sutcliffe, Deping Wang, Yusheng Wu, Yanming Du
  • Patent number: 8188054
    Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, n is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl hgroup, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 29, 2012
    Assignee: Georgia Tech Research Corporation
    Inventor: Adegboyega Oyelere
  • Patent number: 8173609
    Abstract: New macrolide general compounds of formula I with improved activity making them useful for inhibiting human phosphodiesterase 4 and treating chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: May 8, 2012
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
  • Patent number: 8143227
    Abstract: Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: March 27, 2012
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Gordon Jay Dow, Bhaskar Chaudhuri, David Wade Osborne, Barry Calvarese
  • Publication number: 20120058963
    Abstract: The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4? position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-?, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.
    Type: Application
    Filed: November 15, 2011
    Publication date: March 8, 2012
    Applicant: Glaxo Group Limited
    Inventors: Sulejman Alihodzic, Martina Bosnar, Ognjen Culic, Vesna Erakovic Haber, Antun Hutinec, Dubravko Jelic, Goran Kragol, Nikola Marjanovic, Zorica Marusic-Istuk, Marija Ribic, Vanja Vela
  • Patent number: 8124744
    Abstract: Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: February 28, 2012
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masato Kashimura, Madoka Kawamura, Toshifumi Asaka, Kiyoshi Takayama, Haruhisa Ogita
  • Patent number: 8097708
    Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: January 17, 2012
    Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Kaisha, Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Akira Manaka, Haruhisa Ogita, Jun Kurosaka, Madoka Kawamura, Masato Kashimura, Naoki Sasamoto, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara, Dai Kubota
  • Patent number: 8097594
    Abstract: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-? lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: January 17, 2012
    Assignee: Wockhardt Ltd.
    Inventors: Milind Dattatraya Sindkhedkar, Vijaya Narayan Desai, Rajesh Maganlal Loriya, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Rajesh Onkardas Bora, Santosh Devidas Diwakar, Ganesh Rajaram Jadhav, Shivaji Sampatrao Pawar
  • Patent number: 8080529
    Abstract: The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4? position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-?, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: December 20, 2011
    Assignee: Glaxo Group Limited
    Inventors: Sulejman Alihodzic, Martina Bosnar, Ognjen Culic, Vesna Erakovic Haber, Antun Hutinec, Dubravko Jelic, Goran Kragol, Nikola Marjanovic, Zorica Marusic-Istuk, Marija Ribic, Vanja Vela
  • Patent number: 8076301
    Abstract: Disclosed herein are 10-desmethyl, 10 substituted-macrolides, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them. The 10-desmethyl macrolides are particularly useful as antibiotics.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: December 13, 2011
    Assignee: C10 Pharma AS
    Inventors: Kjell Undheim, Solvi Gunnes